<DOC>
	<DOC>NCT00090584</DOC>
	<brief_summary>The primary aim of this study is to test if the addition of behavioral treatment to drug therapy for the treatment of urge incontinence will increase the number of patients who can discontinue drug therapy and sustain a significant reduction of incontinence.</brief_summary>
	<brief_title>Behavior Enhances Drug Reduction of Incontinence (BE-DRI)</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Inclusion: Female Urge predominant incontinence Incontinent &gt; 3 mos Available for 8 mos of followup Exclusion: Pregnancy or &lt; 6 mos postpartum Hypersensitivity to drug (tolterodine) Systemic disease that affects bladder function (e.g., Parkinson's disease, Multiple Sclerosis, spinal cord injury) History of extensive behavior treatment</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Urge urinary incontinence (UUI)</keyword>
	<keyword>Drug/Behavior treatment</keyword>
</DOC>